CD73
ecto-5′-nucleotidase, NT5E
CD73 (Ecto-5′-nucleotidase) is a 70-kD glycosylphosphatidyl inositol (GPI)-anchored cell surface protein encoded by the NT5E gene that plays a crucial role in switching on adenosinergic signaling. CD73 is an ectonucleotidase which catalyzes the terminal step in extracellular adenine nucleotide breakdown: the conversion of AMP to adenosine. Adenosine, which binds to a discrete family of cell surface receptors to initiate intracellular signaling cascades, has been shown to be anti-inflammatory and vasorelaxant.
CD73 has both enzymatic and non-enzymatic functions in cells: as a nucleotidase, CD73 catalyzes the hydrolysis of AMP into adenosine and phosphate, and CD73-generated adenosine plays an important role in tumor immunoescape; moreover, CD73 also functions as a signal and adhesive molecule that can regulate cell interaction with extracellular matrix components, such as laminin and fibronectin, to mediate the invasive and metastatic properties of cancers. Both the enzymatic and non-enzymatic functions of CD73 are involved in cancer-associated processes and are not completely independent of each other. There is ample evidence to show that CD73 is a key regulatory molecule in cancer development and is overexpressed in many cancers, including leukemia, glioblastoma, melanoma, ovarian cancer, esophageal cancer, prostate cancer and breast cancer.
All Product Categories
-
CD73 Related Products (72)
Related Products (72)
-
Recombinant Proteins (10)
-
Antibodies (3)
-
COPCP trisodium
0 ImagesCat. No.: HY-137717A
-
MRS4620
0 ImagesCat. No.: HY-144072CAS No.: 2411665-73-9
-
CD73-IN-9
0 ImagesCat. No.: HY-147590CAS No.: 2766565-88-0CD73-IN-9 (compound 2) is a potent inhibitor of CD73. CD73 can catalyze the production of adenosine from extracellular 5'-phosphate adenosine (5'-AMP), and adenosine can induce immunosuppressive effects and promote tumor proliferation and/or metastasis. CD73-IN-9 can be used for the study of tumor-related diseases.
-
CD73-IN-22
0 ImagesCat. No.: HY-181919CD73-IN-22 (Compound HX-6) is a non-nucleoside CD73 inhibitor with an IC50 of 0.07 μM. When radiolabeled with 68Ga, CD73-IN-22 acts as a PET radiotracer for detecting CD73 expression. When radiolabeled with 177Lu, CD73-IN-22 exhibits anticancer activity against colorectal adenocarcinoma. CD73-IN-22 is applicable to research related to colon adenocarcinoma and breast cancer.
-
HBM1007
0 ImagesCat. No.: HY-P992362HBM1007 is a fully human monoclonal antibody targeting CD73. HBM1007 is an extracellular enzyme expressed on the surface of stromal cells and tumor cells, capable of converting extracellular adenosine monophosphate (AMP) into adenosine, and recognizing CD73 via a unique antigenic epitope. HBM1007 inhibits both CD73-dependent and CD73-independent enzyme activities.
-
PSB-12379 disodium
0 ImagesCat. No.: HY-100747APSB-12379 disodium, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human).
-
ST80
0 ImagesCat. No.: HY-161774CAS No.: 3080717-78-5ST80 is an inhibitor for interaction of OTUD4 and CD73. ST80 decreases CD73 protein level, increases CD73 protein turnover, reduces immune evasion of tumor cells, and thus exhibits antitumor efficacy against immunosuppressive triple-negative breast cancer (TNBC).
-
2,4-Dinitrobenzenesulfonic acid
0 ImagesCat. No.: HY-W095633CAS No.: 89-02-12,4-Dinitrobenzenesulfonic acid (Compound 3) is a ecto-5'-Nucleotidase (CD73) inhibitor with a Ki value of 63 μM for human and 144 μM for rat. 2,4-Dinitrobenzenesulfonic acid can inhibit the hydrolysis of adenosine monophosphate (AMP) to generate adenosine. 2,4-Dinitrobenzenesulfonic acid can be used for the research of cancer.
-
PSB-0963
0 ImagesCat. No.: HY-171805CAS No.: 1213268-73-5PSB-0963 is a selective and competitive ecto-5'-nucleotidase (eN/CD73) inhibitor with a Ki of 150 nM for rat ecto-5'-nucleotidase. PSB-0963 shows high selectivity over other ectonucleotidases (NTPDases 1-3) and P2Y receptors. PSB-0963 can be used for the study of cancer.
-
W-GTF01
0 ImagesCat. No.: HY-185701CAS No.: 951968-89-1W-GTF01 is a MGAT1 inhibitor. W-GTF01 blocks the MGAT1-catalyzed glycosylation of CD73, and inhibits CD73 dimerization, membrane translocation and adenosine production. W-GTF01 restores the function of IFNγ-producing CD8+ T cells, enhances tumor infiltration and activation of CD8+ T cells, and suppresses tumor growth. W-GTF01 can be used in research related to triple-negative breast cancer.
-
ZM514
0 ImagesCat. No.: HY-146759CAS No.: 3032667-17-4ZM514 is a potent CD73 inhibitor with IC50s of 1.39 μM and 14.65 μM for hCD73 and mCD73, respectively. ZM514 has low cytotoxicity. ZM514 can be used for researching anticancer.
-
Enpp-1/3-IN-1
0 ImagesCat. No.: HY-172528Enpp-1/3-IN-1 (Compound 5j) is an ENPP1/ENPP3 inhibitor, with IC50s of 0.59 μM (h-ENPP1) and 0.62 μM (h-ENPP3) respectively. Enpp-1/3-IN-1 also inhibits e5′NT (CD73) and TNAP with IC50s of 0.89 μM (h-e5′NT), 5.12 μM (r-e5′NT) and 1.68 μM (h-TNAP), respectively. Enpp-1/3-IN-1 can be used for cancer research.
-
CD73-IN-15
0 ImagesCat. No.: HY-162554CAS No.: 3044090-88-9
-
NUCC-0227579
0 ImagesCat. No.: HY-184969NUCC-0227579 is a VHL-recruiting PROTAC degrader targeting CD73, with a DC50 of 0.32 μM. NUCC-0227579 synergistically mediates CD73 degradation through the ubiquitin-proteasome pathway and the lysosomal pathway. NUCC-0227579 inhibits the conversion of AMP to adenosine, abrogates adenosine-mediated immunosuppression, upregulates the activities of the NF-κB and NFAT pathways, and enhances the secretion, activation and proliferation levels of IFN-γ and TNF-α. NUCC-0227579 downregulates NAD+ synthesis in tumor cells, and inhibits the proliferation, migration and adhesion abilities of tumor cells under glutamine-deficient conditions. NUCC-0227579 significantly suppresses tumor growth in a humanized NSG mouse model of triple-negative breast cancer.
-
IBI-325
0 ImagesCat. No.: HY-P991634IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.
-
CD73-IN-12
0 ImagesCat. No.: HY-147593CAS No.: 2773502-79-5CD73-IN-12 (compound 9) is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-12 can be used for the study of tumor-related diseases. CD73-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
CD73-IN-18
0 ImagesCat. No.: HY-169189CAS No.: 3037968-61-6CD73-IN-18 (compound 35j) is an orally available inhibitor of extracellular 5-nucleotidase (CD73). CD73-IN-18 can be used in anti-cancer research.
-
S095024
0 ImagesCat. No.: HY-P991612Synonyms: Sym024S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies.
